drugset / Trial / NCT03298373
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
Phase 1
Unknown
43 enrolled
Premier Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · collabUniversity of Washington · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
This is a Phase I multicenter, double-blind, repeat dose, dose-escalating study, in healthy men to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC).
Timeline
- Start
- 2017-11-09
- Primary completion
- 2019-02-05
- Completion
- 2020-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11β-methyl-nortestosterone-dodecylcarbonate | Unknown | 200 mg | Oral |
| Subject | 11β-methyl-nortestosterone-dodecylcarbonate | Unknown | 400 mg | Oral |
Indications
No indication recorded.